WTF@OIS: WHAT’S THE FUTURE @OIS?
•Descargar como PPTX, PDF•
0 recomendaciones•1,196 vistas
Presentation from OIS@ASCRS 2016 Co-Moderators: Gilbert H. Kliman, MD, Managing Director – InterWest Partners Stephen Slade, MD Company Presentations Equinox | John Berdahl, MD, Founder & CEO Presbyopia Therapies | Jim McCollum, Co-Founder Stroma Medical | Doug Daniels, CEO Eyenovia | Curt LaBelle, MD, Director Wicab | Robert Beckman, President & COO
Recomendados
Recomendados
Más contenido relacionado
La actualidad más candente
La actualidad más candente (20)
Destacado
Destacado (9)
Similar a WTF@OIS: WHAT’S THE FUTURE @OIS?
Similar a WTF@OIS: WHAT’S THE FUTURE @OIS? (20)
Más de Healthegy
Más de Healthegy (20)
Último
Último (20)
WTF@OIS: WHAT’S THE FUTURE @OIS?
- 1. WTF@OIS Unconventional innovations challenging conventional wisdom Gilbert H. Kliman, MD Managing Director InterWest Partners Stephen Slade MD, FACS Surgeon Slade & Baker Vision, Houston Co-Moderated By:
- 2. • On your mobile device, open up the messaging APP • Begin a new message and enter 22333 in the “To:” line and OISASCRS in the body – hit send • You are now ready to participate in the live polling! How do I participate?
- 4. Major 20th Century Ophthalmic Innovations in Therapy
- 5. Major 20th Century Ophthalmic Innovations Laser TherapyIntraocular Lens Phacoemulsification
- 6. Sir Harold Ridley, 1940s Biocompatibility of intraocular foreign body Perspex in British fighter pilots could enable intraocular lenses Gerd Meyer-Schwikerath, 1950s Retinal burns seen in observers of solar eclipses could be created therapeutically to treat retinal vascular disease Charles Kelman, 1960s Ultrasonic dental cleaning device could be re-purposed to emulsify the cataractous lens minimally invasively
- 7. WTF@OIS: WHAT’S THE FUTURE @OIS? John Berdahl, MD Founder & CEO Jim McCollum Co-Founder Doug Daniels CEO Curt LaBelle Director Robert Beckman President & COO
- 8. • On your mobile device, open up the messaging APP • Begin a new message and enter 22333 in the “To:” line and OISASCRS in the body – hit send • You are now ready to participate in the live polling! How do I participate?
- 9. John Berdahl, MD Founder & CEO
- 20. What’s The Future for Liquid Vision? 1. Bright: Major new treatment modality for presbyopia 2. Dim: This will never be a success
- 22. Doug Daniels CEO
- 24. ConfidentialConfidential Mission and Vision: • Leader in Eye Aesthetics • Design, develop and patent a safe and natural eye color change Projected Addressable Market: • 25M colored contact lens wearers worldwide/80% dark to light • 1.9M inquiries/16K volunteers for the trial • 17% of dark eyed individuals/43% of refractive patients • Dark-eyed individuals ages 20-50 w/ relative affluence and desire • Refractive surgeons/clinics & hospitals Corporate Overview
- 25. ConfidentialConfidential Addressable WW Market Opportunity 2.34M WW patients x $5,500 per patient = $10.5 B /year $2.9 B/year Physician Revenue: Company Revenue: $1,250 Click Fee
- 26. ConfidentialConfidential The System Proprietary and Confidential
- 27. ConfidentialConfidential Anatomy and Physiology of Eye Color Change
- 28. ConfidentialConfidential Clinical Study Update – 2Q 2016 Proprietary and Confidential Stage I & II - Costa Rica - Clinica 20/20 - Dosimetry study/Full Iris - 20 patients - Follow for 2-3 months Status - In Stage I - 70% Completed - No Complications - Increasing aesthetic results - Completion 6/16
- 29. ConfidentialConfidential Presentation Summary •Company has world class medical and business advisers •Solid laser engineering and software talent •Demonstrated safety in animal and human clinicals •Highly desire outcome market demand worldwide •Large markets with strong IP coverage •Great fit for the ophthalmic market infrastructure •Positive economic incentives for rapid adoption We hope you will join us to create options for patients and opportunities for the ophthalmic community!
- 34. 40 Eyenovia’s Solution • High-precision Micro-dosing of ophthalmic Rx • 7 microliters vs. 50-70 microliters in eyedrops • Charged to adhere to the cornea • Eliminates overflow and delivers directly to ocular surface • “Smart” features to track dosing history • Piezoelectric technology to “print” therapeutics Key Issues in Ophthalmology • 100-year old legacy pipetting/dropper paradigm • Overdosing of eye Rx delivers 10X more than eye can hold • Overdosing of active drug and preservative • Hard for patients to instill eye drops (elderly, arthritis) • Excess dosing can lead to ocular and systemic side effects EYENOVIA AT A GLANCE Topical microdrops for high precision, smart delivery of eye pharmaceuticals
- 35. 41 EYENOVIA: MICRO-DOSING AND SYSTEMIC TOXICITY Microdose can improve therapeutic profile of many existing and new formulations Plasma AUC 15-fold reduction Timolol 40 µL vs 3 µL 4-fold more heart rate depression with standard Timolol drops ARVO 2014: http://iovs.arvojournals.org/article.aspx?articleid=2270053 • 3µL microdose leads to 15 fold reduction in systemic AUC • 10-fold reduction in systemic AUC leads to 4-fold reduction in hear rate depression Plasma Timolol® (40 µL) Timolol® (3 µL) Cmax 8.8 0.8 Tmax 0.5 0.5 T1/2 0.7 0.4 AUC0.5-8hours 8.6 0.5 Ratio AUC0.5-8hours 40 µL versus 3 µL 15.6 Acta Ophthalmol Scand. 2005 Dec;83(6):723-8
- 36. 42 Strategy Improved Ophthalmics in $19B Market Advantages: • Higher therapeutic index- improved safety (topical and systemic) • Enables FDA path for combination products – Lower dose – Improved safety profile • Life cycle management for existing therapeutics • Optimized profile and technical success of new Rx (dry eye, glaucoma)
- 37. 43 Glaucoma Timolol PGA-Timo Combo PHN 400 In-office Pipeline: Launch 2-3 late stage programs in 2017 Products: Target FDA approval of 2-3 branded ophthalmic products by 2019 3 YEAR HORIZON EYENOVIA PLAN Y1 Y2 Y3 Phase II/III Phase II/III Phase II/III
- 41. Robert Beckman President & COO
- 42. BrainPort® V100 Electronic Vision Aid ROBERT BECKMAN CEO - WICAB, INC.
- 43. How Do the Blind Perceive Their Surroundings? •They form a mental image using their remaining senses: • Touch – a white cane provides a single point of contact • Hearing – echoes are amazing •BrainPort® V100 vision aid provides 400 points of contact and streaming patterns to refine that image.
- 44. How Does BrainPort® V100 Work? • Images from a glasses mounted video camera are processed and displayed on the tongue using an array of electrodes • Users learn to interpret stimulation as the scene around them
- 45. A Profoundly Blind User
- 46. BrainPort® V100 Benefits • Users enjoy increased mobility, independence, and confidence • Enhanced socialization with sighted people • Increased training and job opportunities
- 47. The Future of BrainPort • Hands free control and wireless connectivity to a smart phone or tablet • Platform of wireless computer vision apps similar to the driverless car
- 48. BrainPort® – Computer Vision for the Blind •Wicab is pursuing reimbursement in USA, France, & China •Sells for less than 10% of a retinal implant and provides similar benefits •Not limited by etiology and useable by both acquired and congenitally blind •No surgical intervention required